⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,834.65
−0.29%
FTSE ADX
9,829.37
+0.47%
TASI
9,952.06
−1.69%
QE Index
8,598.42
−0.40%
S&P 500
7,712.57
+0.28%
Nasdaq 100
29,490.28
−0.13%
Nifty 50
23,087.00
+0.87%
Sensex
74,549.32
+0.94%
KSE-100
165,151.64
+0.00%
DFM:EMIRATESNBD
AED 31.58
+0.25%
ADX:IHC
AED 356.60
+1.31%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.55
−0.70%
NAS:NVDA
$216.47
−0.29%
NYSE:TSM
$425.08
+1.16%
NSE:RELIANCE
₹1,222.60
+1.71%
KAR:OGDC
Rs 300.01
+0.18%
Gold
$4,123.63
−0.04%
Brent
$110.27
+1.09%
BTC
$82,707.13
−0.28%
ETH
$2,442.29
−0.18%
DFM General
5,834.65
−0.29%
FTSE ADX
9,829.37
+0.47%
TASI
9,952.06
−1.69%
QE Index
8,598.42
−0.40%
S&P 500
7,712.57
+0.28%
Nasdaq 100
29,490.28
−0.13%
Nifty 50
23,087.00
+0.87%
Sensex
74,549.32
+0.94%
KSE-100
165,151.64
+0.00%
DFM:EMIRATESNBD
AED 31.58
+0.25%
ADX:IHC
AED 356.60
+1.31%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.55
−0.70%
NAS:NVDA
$216.47
−0.29%
NYSE:TSM
$425.08
+1.16%
NSE:RELIANCE
₹1,222.60
+1.71%
KAR:OGDC
Rs 300.01
+0.18%
Gold
$4,123.63
−0.04%
Brent
$110.27
+1.09%
BTC
$82,707.13
−0.28%
ETH
$2,442.29
−0.18%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Closed
🇸🇦
Saudi Arabia
Tadawul · TASI
Closed
🇶🇦
Qatar
QSE · QE General
Closed
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Closed
🇮🇳
India
NSE · BSE · Nifty 50
Open
🇵🇰
Pakistan
PSX · KSE-100
Closed
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
Markets
›
United States
› NYSE
› LLY
E
Eli Lilly and Co
NYSE:LLY
Healthcare
CBOE:SPESG
NASDAQ:NQUSLG
$1,283.66
+3.49%
At close
At close · Wed 21 Oct · ≈
AED 4,714.24
· Market cap
$1.21T
· Next earnings
Thu 29 Oct
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
Ownership
Options
Shorts
News
Profile
Eli Lilly and Co · News · TradingHolo
LLY news
Headlines tagged to this company
TH
Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient
The Motley Fool · 67 d ago
CN
Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'
CNBC · 69 d ago
SE
I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)
Seeking Alpha · 70 d ago
PR
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
PRNewsWire · 70 d ago
TH
Why Eli Lilly Topped the Market Today
The Motley Fool · 71 d ago
MA
Eli Lilly and Company Q2 Earnings Call Highlights
MarketBeat · 74 d ago
TH
Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem
The Motley Fool · 74 d ago
SE
Eli Lilly: Fine Q2 2026 Results, But Alertness Required
Seeking Alpha · 75 d ago
ZA
LLY Q2 Earnings Call Raises Outlook as Foundayo Gains Traction
Zacks Investment Research · 76 d ago
CN
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
CNBC · 76 d ago
SE
Eli Lilly Q2: Strong Results Further Strengthen The Investment Thesis
Seeking Alpha · 76 d ago
TH
Why Eli Lilly Stock Climbed Today
The Motley Fool · 76 d ago
SE
Eli Lilly and Company (LLY) Q2 2026 Earnings Call Transcript
Seeking Alpha · 76 d ago
CN
Market Close: Stock Rally Fades, Job Growth Weakens, Strong Earnings Boost Eli Lilly 8-5-2026
CNBC Television · 77 d ago
PR
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
PRNewsWire · 77 d ago
GL
Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly's Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer
GlobeNewsWire · 78 d ago
PR
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
PRNewsWire · 79 d ago
← Previous
End of the feed